Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers

Gastroenterology

Volumn 149, Issue 5, 2015, Pages 1204-1225.e12

  Okugawa, Yoshinaga ^a   Grady, William M ^b,c   Goel, Ajay ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

DNA Methylation; Histone Modification; Long Noncoding RNA; MicroRNA

Indexed keywords

ANTINEOPLASTIC AGENT; APC PROTEIN; ATM PROTEIN; BETA CATENIN; CALCITONIN; CCAAT ENHANCER BINDING PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DACARBAZINE; DNA METHYLTRANSFERASE 3A; DNA METHYLTRANSFERASE 3B; FLUOROURACIL; FOLINIC ACID; GLUTATHIONE TRANSFERASE P1; K RAS PROTEIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MICRORNA; MULTIDRUG RESISTANCE PROTEIN 1; OSTEOGENIN; OXALIPLATIN; PROTEIN MLH1; SECRETED FRIZZLED RELATED PROTEIN 2; SEPTIN 9; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTION FACTOR RUNX3; TUMOR MARKER; UNCLASSIFIED DRUG; UNTRANSLATED RNA; UVOMORULIN; VIMENTIN; WNT5A PROTEIN; BIOLOGICAL MARKER; HISTONE;

ARTICLE; BLOOD ANALYSIS; CANCER DIAGNOSIS; COLORECTAL CANCER; DNA METHYLATION; DRUG RESPONSE; EPIGENETICS; FECES ANALYSIS; GENE MUTATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT INTERSPERSED REPEAT; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROCEDURES; PROGNOSIS;

BIOMARKERS; COLORECTAL NEOPLASMS; DNA METHYLATION; EPIGENOMICS; GENE EXPRESSION REGULATION; HISTONES; HUMANS; MICRORNAS; PROGNOSIS; RNA, UNTRANSLATED;

EID: 84943329497     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.07.011     Document Type: Article

References (357)

1. R. Siegel, E. Ward, O. Brawley, and et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths CA Cancer J Clin 61 2011 212 236
2. C.H. Waddington The epigenotype Endeavour 1 1942 18 20
3. A. Bird DNA methylation patterns and epigenetic memory Genes Dev 16 2002 6 21
4. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
5. A.P. Feinberg, and B. Vogelstein Hypomethylation distinguishes genes of some human cancers from their normal counterparts Nature 301 1983 89 92
6. S.E. Goelz, B. Vogelstein, S.R. Hamilton, and et al. Hypomethylation of DNA from benign and malignant human colon neoplasms Science 228 1985 187 190
7. S.B. Baylin, J.W. Hoppener, A. de Bustros, and et al. DNA methylation patterns of the calcitonin gene in human lung cancers and lymphomas Cancer Res 46 1986 2917 2922
8. V. Greger, E. Passarge, W. Hopping, and et al. Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma Hum Genet 83 1989 155 158
9. T. Sakai, J. Toguchida, N. Ohtani, and et al. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene Am J Hum Genet 48 1991 880 888
10. N. Ohtani-Fujita, T. Fujita, A. Aoike, and et al. CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene Oncogene 8 1993 1063 1067
11. J.G. Herman, A. Merlo, L. Mao, and et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers Cancer Res 55 1995 4525 4530
12. M.F. Kane, M. Loda, G.M. Gaida, and et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines Cancer Res 57 1997 808 811
13. K. Yoshiura, Y. Kanai, A. Ochiai, Y. Shimoyama, T. Sugimura, and S. Hirohashi Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas Proc Natl Acad Sci U S A 92 1995 7416 7419
14. J.G. Herman, and S.B. Baylin Gene silencing in cancer in association with promoter hypermethylation N Engl J Med 349 2003 2042 2054
15. M. Weber, I. Hellmann, M.B. Stadler, and et al. Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome Nat Genet 39 2007 457 466
16. F. Antequera, and A. Bird Number of CpG islands and genes in human and mouse Proc Natl Acad Sci U S A 90 1993 11995 11999
17. D. Takai, and P.A. Jones Comprehensive analysis of CpG islands in human chromosomes 21 and 22 Proc Natl Acad Sci U S A 99 2002 3740 3745
18. I.J. van Vlodrop, H.E. Niessen, S. Derks, and et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res 17 2011 4225 42331
19. M. Rodriguez-Paredes, and M. Esteller Cancer epigenetics reaches mainstream oncology Nat Med 17 2011 330 339
20. M. Esteller Epigenetic gene silencing in cancer: the DNA hypermethylome Hum Mol Genet 16 Spec No 1 2007 R50 R59
21. L. Lopez-Serra, and M. Esteller Proteins that bind methylated DNA and human cancer: reading the wrong words Br J Cancer 98 2008 1881 1885
22. A. Meissner, T.S. Mikkelsen, H. Gu, and et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells Nature 454 2008 766 770
23. A. Doi, I.H. Park, B. Wen, and et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts Nat Genet 41 2009 1350 1353
24. R.A. Irizarry, C. Ladd-Acosta, B. Wen, and et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores Nat Genet 41 2009 178 186
25. M. Toyota, N. Ahuja, M. Ohe-Toyota, and et al. CpG island methylator phenotype in colorectal cancer Proc Natl Acad Sci U S A 96 1999 8681 8686
26. D.J. Weisenberger, K.D. Siegmund, M. Campan, and et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat Genet 38 2006 787 793
27. M. Toyota, M. Ohe-Toyota, N. Ahuja, and et al. Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype Proc Natl Acad Sci U S A 97 2000 710 715
28. M. van Rijnsoever, F. Grieu, H. Elsaleh, and et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands Gut 51 2002 797 802
29. N. Hawkins, M. Norrie, K. Cheong, and et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability Gastroenterology 122 2002 1376 1387
30. W.S. Samowitz, H. Albertsen, J. Herrick, and et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer Gastroenterology 129 2005 837 845
31. S. Popat, R. Hubner, and R.S. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 2005 609 618
32. R. Ward, A. Meagher, I. Tomlinson, T. O'Connor, and et al. Microsatellite instability and the clinicopathological features of sporadic colorectal cancer Gut 48 2001 821 829
33. H. Hampel, W.L. Frankel, E. Martin, and et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer) N Engl J Med 352 2005 1851 1860
34. H. Hampel, W.L. Frankel, E. Martin, and et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer J Clin Oncol 26 2008 5783 5788
35. L. Wang, J.M. Cunningham, J.L. Winters, and et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair Cancer Res 63 2003 5209 5212
36. S. Ogino, K. Nosho, G.J. Kirkner, and et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer Gut 58 2009 90 96
37. B. Vogelstein, E.R. Fearon, S.R. Hamilton, and et al. Genetic alterations during colorectal-tumor development N Engl J Med 319 1988 525 532
38. V.V. Lao, and W.M. Grady Epigenetics and colorectal cancer Nat Rev Gastroenterol Hepatol 8 2011 686 700
39. D. Colussi, G. Brandi, F. Bazzoli, and et al. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention Int J Mol Sci 14 2013 16365 16385
40. H. Li, L. Myeroff, D. Smiraglia, and et al. SLC5A8, a sodium transporter, is a tumor suppressor gene silenced by methylation in human colon aberrant crypt foci and cancers Proc Natl Acad Sci U S A 100 2003 8412 8417
41. J. Qi, Y.Q. Zhu, J. Luo, and W.H. Tao Hypermethylation and expression regulation of secreted frizzled-related protein genes in colorectal tumor World J Gastroenterol 12 2006 7113 7117
42. H.R. Moinova, W.D. Chen, L. Shen, and et al. HLTF gene silencing in human colon cancer Proc Natl Acad Sci U S A 99 2002 4562 4567
43. L. Peng, J. Hu, S. Li, and et al. Aberrant methylation of the PTCH1 gene promoter region in aberrant crypt foci Int J Cancer 132 2013 E18 E25
44. M. Esteller, M. Toyota, M. Sanchez-Cespedes, and et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis Cancer Res 60 2000 2368 2371
45. A.O. Chan, R.R. Broaddus, P.S. Houlihan, and et al. CpG island methylation in aberrant crypt foci of the colorectum Am J Pathol 160 2002 1823 1830
46. T.F. Imperiale, D.F. Ransohoff, and S.H. Itzkowitz Multitarget stool DNA testing for colorectal-cancer screening N Engl J Med 371 2014 187 188
47. J.R. Jass, and M. Smith Sialic acid and epithelial differentiation in colorectal polyps and cancer - a morphological, mucin and lectin histochemical study Pathology 24 1992 233 242
48. E.J. Sawyer, A. Cerar, A.M. Hanby, and et al. Molecular characteristics of serrated adenomas of the colorectum Gut 51 2002 200 206
49. H. Uchida, H. Ando, K. Maruyama, and et al. Genetic alterations of mixed hyperplastic adenomatous polyps in the colon and rectum Jpn J Cancer Res 89 1998 299 306
50. T. Yamamoto, K. Konishi, T. Yamochi, and et al. No major tumorigenic role for beta-catenin in serrated as opposed to conventional colorectal adenomas Br J Cancer 89 2003 152 157
51. M.J. Makinen Colorectal serrated adenocarcinoma Histopathology 50 2007 131 150
52. M. Dhir, S. Yachida, L. Van Neste, and et al. Sessile serrated adenomas and classical adenomas: an epigenetic perspective on premalignant neoplastic lesions of the gastrointestinal tract Int J Cancer 129 2011 1889 1898
53. R.J. Guo, S. Funakoshi, H.H. Lee, and et al. The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex Carcinogenesis 31 2010 159 166
54. M.R. Kohonen-Corish, N.D. Sigglekow, J. Susanto, and et al. Promoter methylation of the mutated in colorectal cancer gene is a frequent early event in colorectal cancer Oncogene 26 2007 4435 4441
55. E. Kaji, T. Uraoka, J. Kato, and et al. Externalization of saw-tooth architecture in small serrated polyps implies the presence of methylation of IGFBP7 Dig Dis Sci 57 2012 1261 1270
56. L. Kriegl, J. Neumann, M. Vieth, and et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer Mod Pathol 24 2011 1015 1022
57. R.Z. Chen, U. Pettersson, C. Beard, and et al. DNA hypomethylation leads to elevated mutation rates Nature 395 1998 89 93
58. T.M. Holm, L. Jackson-Grusby, T. Brambrink, and et al. Global loss of imprinting leads to widespread tumorigenesis in adult mice Cancer Cell 8 2005 275 285
59. F. Gaudet, J.G. Hodgson, A. Eden, and et al. Induction of tumors in mice by genomic hypomethylation Science 300 2003 489 492
60. K. Suzuki, I. Suzuki, A. Leodolter, and et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage Cancer Cell 9 2006 199 207
61. E.S. Lander, L.M. Linton, B. Birren, and et al. Initial sequencing and analysis of the human genome Nature 409 2001 860 921
62. E. Yamamoto, M. Toyota, H. Suzuki, and et al. LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis Cancer Epidemiol Biomarkers Prev 17 2008 2555 2564
63. J. Pattamadilok, N. Huapai, P. Rattanatanyong, and et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer Int J Gynecol Cancer 18 2008 711 717
64. A. Goel, R.M. Xicola, T.P. Nguyen, and et al. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency Gastroenterology 138 2010 1854 1862
65. S. Ogino, T. Kawasaki, K. Nosho, and et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer Int J Cancer 122 2008 2767 2773
66. M.R. Estecio, V. Gharibyan, L. Shen, and et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability PLoS One 2 2007 e399
67. S. Ogino, K. Nosho, G.J. Kirkner, and et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer J Natl Cancer Inst 100 2008 1734 1738
68. M. Antelo, F. Balaguer, J. Shia, and et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer PLoS One 7 2012 e45357
69. J.B. Ahn, W.B. Chung, O. Maeda, and et al. DNA methylation predicts recurrence from resected stage III proximal colon cancer Cancer 117 2011 1847 1854
70. Y.Y. Rhee, M.J. Kim, J.M. Bae, and et al. Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on L1 methylation level Ann Surg Oncol 19 2012 3441 3448
71. E.M. Wolff, H.M. Byun, H.F. Han, and et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer PLoS Genet 6 2010 e1000917
72. K. Hur, P. Cejas, J. Feliu, and et al. Hypomethylation of long interspersed nuclear element-1 (LINE-1) leads to activation of proto-oncogenes in human colorectal cancer metastasis Gut 63 2014 635 646
73. R.A. Cairns, and T.W. Mak Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities Cancer discovery 3 2013 730 741
74. S. Kriaucionis, and N. Heintz The nuclear DNA base 5-hydroxymethylcytosine is present in Purkinje neurons and the brain Science 324 2009 929 930
75. M. Tahiliani, K.P. Koh, Y. Shen, and et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1 Science 324 2009 930 935
76. Y. Kudo, K. Tateishi, K. Yamamoto, and et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation Cancer Sci 103 2012 670 676
77. W. Li, and M. Liu Distribution of 5-hydroxymethylcytosine in different human tissues J Nucleic Acids 2011 2011 870726
78. F. Neri, D. Dettori, D. Incarnato, and et al. TET1 is a tumour suppressor that inhibits colon cancer growth by derepressing inhibitors of the WNT pathway Oncogene 34 2014 4168 4176
79. M.D. Stachler, E. Rinehart, N. Lindeman, and et al. Novel molecular insights from routine genotyping of colorectal carcinomas Human pathology 46 2015 507 513
80. J.F. Paone, T.P. Waalkes, R.R. Baker, and et al. Serum UDP-galactosyl transferase as a potential biomarker for breast carcinoma J Surg Oncol 15 1980 59 66
81. Biomarkers Definitions Working G Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
82. D. Sidransky, T. Tokino, S.R. Hamilton, K.W. Kinzler, B. Levin, P. Frost, and B. Vogelstein Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors Science 256 1992 102 105
83. H.M. Muller, M. Oberwalder, H. Fiegl, M. Morandell, G. Goebel, M. Zitt, M. Muhlthaler, D. Ofner, R. Margreiter, and M. Widschwendter Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363 2004 1283 1285
84. Z. Huang, L. Li, and J. Wang Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions Dig Dis Sci 52 2007 2287 2291
85. W.D. Chen, Z.J. Han, J. Skoletsky, and et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene J Natl Cancer Inst 97 2005 1124 1132
86. S.H. Itzkowitz, L. Jandorf, R. Brand, and et al. Improved fecal DNA test for colorectal cancer screening Clin Gastroenterol Hepatol 5 2007 111 117
87. S. Itzkowitz, R. Brand, L. Jandorf, and et al. A simplified, noninvasive stool DNA test for colorectal cancer detection Am J Gastroenterol 103 2008 2862 2870
88. W.K. Leung, K.F. To, E.P. Man, and et al. Detection of hypermethylated DNA or cyclooxygenase-2 messenger RNA in fecal samples of patients with colorectal cancer or polyps Am J Gastroenterol 102 2007 1070 1076
89. D.R. Wang, and D. Tang Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening World J Gastroenterol 14 2008 524 531
90. S.C. Glockner, M. Dhir, J.M. Yi, and et al. Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer Cancer Res 69 2009 4691 4699
91. D.M. Hellebrekers, M.H. Lentjes, S.M. van den Bosch, and et al. GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer Clin Cancer Res 15 2009 3990 3997
92. V. Melotte, M.H. Lentjes, S.M. van den Bosch, and et al. N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer J Natl Cancer Inst 101 2009 916 927
93. Z. Petko, M. Ghiassi, A. Shuber, and et al. Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps Clin Cancer Res 11 2005 1203 1209
94. G.P. Lidgard, M.J. Domanico, J.J. Bruinsma, and et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia Clin Gastroenterol Hepatol 11 2013 1313 1318
95. B.B. Lee, E.J. Lee, E.H. Jung, and et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer Clin Cancer Res 15 2009 6185 6191
96. M.S. Pepe, and T.A. Alonzo Comparing disease screening tests when true disease status is ascertained only for screen positives Biostatistics 2 2001 249 260
97. T.F. Imperiale, D.F. Ransohoff, S.H. Itzkowitz, and et al. Multitarget stool DNA testing for colorectal-cancer screening N Engl J Med 370 2014 1287 1297
98. B. Shapiro, M. Chakrabarty, E.M. Cohn, and et al. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease Cancer 51 1983 2116 2120
99. H. Nawroz, W. Koch, P. Anker, and et al. Microsatellite alterations in serum DNA of head and neck cancer patients Nat Med 2 1996 1035 1037
100. K. Hibi, C.R. Robinson, S. Booker, and et al. Molecular detection of genetic alterations in the serum of colorectal cancer patients Cancer Res 58 1998 1405 1407
101. M. Esteller, M. Sanchez-Cespedes, R. Rosell, and et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients Cancer Res 59 1999 67 70
102. I.H. Wong, Y.M. Lo, J. Zhang, and et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients Cancer Res 59 1999 71 73
103. J.M. Silva, G. Dominguez, M.J. Villanueva, and et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients Br J Cancer 80 1999 1262 1264
104. D.D. Leipe, Y.I. Wolf, E.V. Koonin, and et al. Classification and evolution of P-loop GTPases and related ATPases J Mol Biol 317 2002 41 72
105. P.J. Sheffield, C.J. Oliver, B.E. Kremer, and et al. Borg/septin interactions and the assembly of mammalian septin heterodimers, trimers, and filaments J Biol Chem 278 2003 3483 3488
106. C. Lofton-Day, F. Model, T. Devos, and et al. DNA methylation biomarkers for blood-based colorectal cancer screening Clin Chem 54 2008 414 423
107. T.R. Church, M. Wandell, C. Lofton-Day, and et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer Gut 63 2014 317 325
108. P. Jin, Q. Kang, X. Wang, and et al. Performance of a second generation methylated SEPT9 test in detecting colorectal neoplasm J Gastroenterol Hepatol 30 2015 830 833
109. M.P. Ebert, F. Model, S. Mooney, and et al. Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas Gastroenterology 131 2006 1418 1430
110. W.K. Leung, K.F. To, E.P. Man, and et al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer Am J Gastroenterol 100 2005 2274 2279
111. M. Wallner, A. Herbst, A. Behrens, and et al. Methylation of serum DNA is an independent prognostic marker in colorectal cancer Clin Cancer Res 12 2006 7347 7352
112. A. Herbst, K. Rahmig, P. Stieber, and et al. Methylation of NEUROG1 in serum is a sensitive marker for the detection of early colorectal cancer Am J Gastroenterol 106 2011 1110 1118
113. M. Li, W.D. Chen, N. Papadopoulos, and et al. Sensitive digital quantification of DNA methylation in clinical samples Nat Biotechnol 27 2009 858 863
114. L. Shen, P.J. Catalano, A.B. Benson III, and et al. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy Clin Cancer Res 13 2007 6093 6098
115. J.C. Kim, J.S. Choi, S.A. Roh, and et al. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas Ann Surg Oncol 17 2010 1767 1776
116. S. Ogino, J.A. Meyerhardt, T. Kawasaki, and et al. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma Virchows Arch 450 2007 529 537
117. I. Zlobec, M.P. Bihl, A. Foerster, and et al. Stratification and prognostic relevance of jass's molecular classification of colorectal cancer Front Oncol 2 2012 7
118. M. van Rijnsoever, H. Elsaleh, D. Joseph, and et al. CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer Clin Cancer Res 9 2003 2898 2903
119. S. Lee, N.Y. Cho, M. Choi, and et al. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation Pathol Int 58 2008 104 113
120. R.K. Pai, P. Jayachandran, A.C. Koong, and et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features Am J Surg Pathol 36 2012 744 752
121. P. Lochhead, A. Kuchiba, Y. Imamura, and et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication J Natl Cancer Inst 105 2013 1151 1156
122. H. Suzuki, E. Yamamoto, R. Maruyama, and et al. Biological significance of the CpG island methylator phenotype Biochem Biophys Res Commun 455 2014 35 42
123. Y.Y. Juo, F.M. Johnston, D.Y. Zhang, and et al. Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis Ann Oncol 25 2014 2314 2327
124. Y. Baba, K. Nosho, K. Shima, and et al. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis Gastroenterology 139 2010 1855 1864
125. T.K. Nilsson, Z.M. Lof-Ohlin, and X.F. Sun DNA methylation of the p14ARF, RASSF1A and APC1A genes as an independent prognostic factor in colorectal cancer patients Int J Oncol 42 2013 127 133
126. T. Nagasaka, G.B. Sharp, K. Notohara, and et al. Hypermethylation of O6-methylguanine-DNA methyltransferase promoter may predict nonrecurrence after chemotherapy in colorectal cancer cases Clin Cancer Res 9 2003 5306 5312
127. M.X. Draht, K.M. Smits, B. Tournier, and et al. Promoter CpG island methylation of RET predicts poor prognosis in stage II colorectal cancer patients Mol Oncol 8 2014 679 688
128. Z.M. Zhang, Y. Wang, R. Huang, and et al. TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer J Cancer Res Clin Oncol 140 2014 2119 2127
129. S.J. Park, S.M. Kim, Y.S. Hong, and et al. TFAP2E methylation status and prognosis of patients with radically resected colorectal cancer Oncology 88 2015 122 132
130. B.H. Min, J.M. Bae, E.J. Lee, and et al. The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy BMC Cancer 11 2011 344
131. R. Jover, T.P. Nguyen, L. Perez-Carbonell, and et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer Gastroenterology 140 2011 1174 1181
132. S. Shiovitz, M.M. Bertagnolli, L.A. Renfro, et al. Alliance for Clinical Trials in O CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer Gastroenterology 147 2014 637 645
133. M. Weller, R. Stupp, M.E. Hegi, and et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice Neuro Oncol 14 Suppl 4 2012 iv100 iv108
134. M.P. Ebert, M. Tanzer, B. Balluff, and et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer N Engl J Med 366 2012 44 53
135. C. Moutinho, A. Martinez-Cardus, C. Santos, and et al. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer J Natl Cancer Inst 106 2014 djt322
136. D.P. Slaughter, H.W. Southwick, and W. Smejkal Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin Cancer 6 1953 963 968
137. J.P. Issa, Y.L. Ottaviano, P. Celano, S.R. Hamilton, and et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon Nat Genet 7 1994 536 540
138. H. Cui, P. Onyango, S. Brandenburg, and et al. Loss of imprinting in colorectal cancer linked to hypomethylation of H19 and IGF2 Cancer Res 62 2002 6442 6446
139. H. Suzuki, D.N. Watkins, K.W. Jair, and et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer Nat Genet 36 2004 417 422
140. K. Kawakami, A. Ruszkiewicz, G. Bennett, and et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer Br J Cancer 94 2006 593 598
141. L. Shen, Y. Kondo, G.L. Rosner, and et al. MGMT promoter methylation and field defect in sporadic colorectal cancer J Natl Cancer Inst 97 2005 1330 1338
142. H. Kamiyama, K. Suzuki, T. Maeda, and et al. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers Oncogene 31 2012 5029 5037
143. J.P. Issa Aging and epigenetic drift: a vicious cycle J Clin Invest 124 2014 24 29
144. N. Ahuja, Q. Li, A.L. Mohan, and et al. Aging and DNA methylation in colorectal mucosa and cancer Cancer Res 58 1998 5489 5494
145. N. Ahuja, and J.P. Issa Aging, methylation and cancer Histol Histopathol 15 2000 835 842
146. M.F. Fraga, E. Ballestar, M.F. Paz, and et al. Epigenetic differences arise during the lifetime of monozygotic twins Proc Natl Acad Sci U S A 102 2005 10604 10609
147. J.T. Bell, and T.D. Spector DNA methylation studies using twins: what are they telling us? Genome Biol 13 2012 172
148. J.T. Bell, P.C. Tsai, T.P. Yang, and et al. Epigenome-wide scans identify differentially methylated regions for age and age-related phenotypes in a healthy ageing population PLoS Genet 8 2012 e1002629
149. A.J. Andrews, and K. Luger Nucleosome structure(s) and stability: variations on a theme Annu Rev Biophys 40 2011 99 117
150. T. Jenuwein, and C.D. Allis Translating the histone code Science 293 2001 1074 1080
151. S.B. Baylin, and P.A. Jones A decade of exploring the cancer epigenome - biological and translational implications Nat Rev Cancer 11 2011 726 734
152. M.F. Fraga, E. Ballestar, A. Villar-Garea, and et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer Nat Genet 37 2005 391 400
153. H. Tamagawa, T. Oshima, M. Shiozawa, and et al. The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer Oncol Rep 27 2012 637 642
154. A. Benard, I.J. Goossens-Beumer, A.Q. van Hoesel, and et al. Histone trimethylation at H3K4, H3K9 and H4K20 correlates with patient survival and tumor recurrence in early-stage colon cancer BMC Cancer 14 2014 531
155. A. Benard, I.J. Goossens-Beumer, A.Q. van Hoesel, and et al. Nuclear expression of histone deacetylases and their histone modifications predicts clinical outcome in colorectal cancer Histopathology 66 2015 270 282
156. H. Tamagawa, T. Oshima, M. Numata, and et al. Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer Eur J Surg Oncol 39 2013 655 661
157. G. Leszinski, U. Gezer, B. Siegele, and et al. Relevance of histone marks H3K9me3 and H4K20me3 in cancer Anticancer Res 32 2012 2199 2205
158. U. Gezer, D. Ustek, E.E. Yoruker, and et al. Characterization of H3K9me3- and H4K20me3-associated circulating nucleosomal DNA by high-throughput sequencing in colorectal cancer Tumour Biol 34 2013 329 336
159. F.H. Crick, L. Barnett, S. Brenner, and et al. General nature of the genetic code for proteins Nature 192 1961 1227 1232
160. Consortium EP An integrated encyclopedia of DNA elements in the human genome Nature 489 2012 57 74
161. F.F. Costa Non-coding RNAs: new players in eukaryotic biology Gene 357 2005 83 94
162. A. Pauli, J.L. Rinn, and A.F. Schier Non-coding RNAs as regulators of embryogenesis Nat Rev Genet 12 2011 136 149
163. R.C. Lee, R.L. Feinbaum, and V. Ambros The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 Cell 75 1993 843 854
164. B. Wightman, I. Ha, and G. Ruvkun Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans Cell 75 1993 855 862
165. L. He, and G.J. Hannon MicroRNAs: small RNAs with a big role in gene regulation Nat Rev Genet 5 2004 522 531
166. J.T. Mendell MicroRNAs: critical regulators of development, cellular physiology and malignancy Cell Cycle 4 2005 1179 1184
167. S. Vasudevan, Y. Tong, and J.A. Steitz Switching from repression to activation: microRNAs can up-regulate translation Science 318 2007 1931 1934
168. G.A. Calin, C.D. Dumitru, M. Shimizu, and et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia Proc Natl Acad Sci U S A 99 2002 15524 15529
169. O. Slaby, M. Svoboda, J. Michalek, and et al. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application Mol Cancer 8 2009 102
170. K. Motoyama, H. Inoue, Y. Takatsuno, and et al. Over- and under-expressed microRNAs in human colorectal cancer Int J Oncol 34 2009 1069 1075
171. R. Nagel, C. le Sage, B. Diosdado, and et al. Regulation of the adenomatous polyposis coli gene by the miR-135 family in colorectal cancer Cancer Res 68 2008 5795 5802
172. G.M. Arndt, L. Dossey, L.M. Cullen, and et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer BMC Cancer 9 2009 374
173. A.L. Oberg, A.J. French, A.L. Sarver, and et al. miRNA expression in colon polyps provides evidence for a multihit model of colon cancer PLoS One 6 2011 e20465
174. A. Pagliuca, C. Valvo, E. Fabrizi, and et al. Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression Oncogene 32 2013 4806 4813
175. S.M. Johnson, H. Grosshans, J. Shingara, and et al. RAS is regulated by the let-7 microRNA family Cell 120 2005 635 647
176. F. Meng, R. Henson, H. Wehbe-Janek, and et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer Gastroenterology 133 2007 647 658
177. L. Xu, Y. Zhang, H. Wang, and et al. Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway J Transl Med 12 2014 244
178. B. Xiong, Y. Cheng, L. Ma, and et al. MiR-21 regulates biological behavior through the PTEN/PI-3 K/Akt signaling pathway in human colorectal cancer cells Int J Oncol 42 2013 219 228
179. C. Josse, N. Bouznad, P. Geurts, and et al. Identification of a microRNA landscape targeting the PI3K/Akt signaling pathway in inflammation-induced colorectal carcinogenesis Am J Physiol Gastrointest Liver Physiol 306 2014 G229 G243
180. D. Sun, F. Yu, Y. Ma, and et al. MicroRNA-31 activates the RAS pathway and functions as an oncogenic MicroRNA in human colorectal cancer by repressing RAS p21 GTPase activating protein 1 (RASA1) J Biol Chem 288 2013 9508 9518
181. M. Vogt, J. Munding, M. Gruner, and et al. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas Virchows Arch 458 2011 313 322
182. H. Tazawa, N. Tsuchiya, M. Izumiya, and et al. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells Proc Natl Acad Sci U S A 104 2007 15472 15477
183. Y. Dong, J. Zhao, C.W. Wu, L. Zhang, X. Liu, W. Kang, W.W. Leung, N. Zhang, F.K. Chan, J.J. Sung, S.S. Ng, and J. Yu Tumor suppressor functions of miR-133a in colorectal cancer Mol Cancer Res 11 2013 1051 1060
184. C.E. King, M. Cuatrecasas, A. Castells, and et al. LIN28B promotes colon cancer progression and metastasis Cancer Res 71 2011 4260 4268
185. H.C. Tu, S. Schwitalla, Z. Qian, and et al. LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans Genes Dev 29 2015 1074 1086
186. T. Papagiannakopoulos, A. Shapiro, and K.S. Kosik MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells Cancer Res 68 2008 8164 8172
187. F. Liu, X. Kong, L. Lv, and et al. TGF-beta1 acts through miR-155 to down-regulate TP53INP1 in promoting epithelial-mesenchymal transition and cancer stem cell phenotypes Cancer Lett 359 2015 288 298
188. P.A. Gregory, C.P. Bracken, E. Smith, and et al. An autocrine TGF-beta/ZEB/miR-200 signaling network regulates establishment and maintenance of epithelial-mesenchymal transition Mol Biol Cell 22 2011 1686 1698
189. K.J. Schmitz, S. Hey, A. Schinwald, and et al. Differential expression of microRNA 181b and microRNA 21 in hyperplastic polyps and sessile serrated adenomas of the colon Virchows Arch 455 2009 49 54
190. K. Nosho, H. Igarashi, M. Nojima, and et al. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway Carcinogenesis 35 2014 776 783
191. D.K. Rex, D.J. Ahnen, J.A. Baron, and et al. Serrated lesions of the colorectum: review and recommendations from an expert panel Am J Gastroenterol 107 2012 1315 1329 quiz 1314, 1330
192. M. Ito, K. Mitsuhashi, H. Igarashi, and et al. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions Int J Cancer 135 2014 2507 2515
193. M. Yamauchi, T. Morikawa, A. Kuchiba, and et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum Gut 61 2012 847 854
194. M. Yamauchi, P. Lochhead, T. Morikawa, and et al. Colorectal cancer: a tale of two sides or a continuum? Gut 61 2012 794 797
195. E.E. Creemers, A.J. Tijsen, and Y.M. Pinto Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110 2012 483 495
196. J.D. Arroyo, J.R. Chevillet, E.M. Kroh, and et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma Proc Natl Acad Sci U S A 108 2011 5003 5008
197. A. Turchinovich, L. Weiz, A. Langheinz, and et al. Characterization of extracellular circulating microRNA Nucleic Acids Res 39 2011 7223 7233
198. K.C. Vickers, B.T. Palmisano, B.M. Shoucri, and et al. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins Nat Cell Biol 13 2011 423 433
199. H. Valadi, K. Ekstrom, A. Bossios, and et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells Nat Cell Biol 9 2007 654 659
200. Y. Toiyama, M. Takahashi, K. Hur, and et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer J Natl Cancer Inst 105 2013 849 859
201. H. Ogata-Kawata, M. Izumiya, D. Kurioka, and et al. Circulating exosomal microRNAs as biomarkers of colon cancer PLoS One 9 2014 e92921
202. S.S. Chim, T.K. Shing, E.C. Hung, and et al. Detection and characterization of placental microRNAs in maternal plasma Clin Chem 54 2008 482 490
203. E.K. Ng, W.W. Chong, H. Jin, and et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening Gut 58 2009 1375 1381
204. Z. Huang, D. Huang, S. Ni, and et al. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer Int J Cancer 127 2010 118 126
205. A.J. Schetter, S.Y. Leung, J.J. Sohn, and et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma JAMA 299 2008 425 436
206. K. Schee, S. Lorenz, M.M. Worren, and et al. Deep sequencing the microRNA transcriptome in colorectal cancer PLoS One 8 2013 e66165
207. Z. Kanaan, S.N. Rai, M.R. Eichenberger, and et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer Ann Surg 256 2012 544 551
208. G.H. Liu, Z.G. Zhou, R. Chen, and et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer Tumour Biol 34 2013 2175 2181
209. Z.C. Lv, Y.S. Fan, H.B. Chen, and et al. Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer Tumour Biol 36 2015 1619 1625
210. X.X. Pu, G.L. Huang, H.Q. Guo, and et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression J Gastroenterol Hepatol 25 2010 1674 1680
211. G.J. Zhang, T. Zhou, Z.L. Liu, and et al. Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma Mol Clin Oncol 1 2013 379 384
212. X. Luo, C. Stock, B. Burwinkel, and et al. Identification and evaluation of plasma microRNAs for early detection of colorectal cancer PLoS One 8 2013 e62880
213. Z. Kanaan, H. Roberts, M.R. Eichenberger, and et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer Ann Surg 258 2013 400 408
214. J. Wang, S.K. Huang, M. Zhao, and et al. Identification of a circulating microRNA signature for colorectal cancer detection PLoS One 9 2014 e87451
215. S. Wang, J. Xiang, Z. Li, and et al. A plasma microRNA panel for early detection of colorectal cancer Int J Cancer 136 2015 152 161
216. A. Link, F. Balaguer, Y. Shen, and et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening Cancer Epidemiol Biomarkers Prev 19 2010 1766 1774
217. C.W. Wu, S.S. Ng, Y.J. Dong, and et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps Gut 61 2012 739 745
218. Y. Koga, N. Yamazaki, Y. Yamamoto, and et al. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test Cancer Epidemiol Biomarkers Prev 22 2013 1844 1852
219. Y. Koga, M. Yasunaga, A. Takahashi, and et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening Cancer Prev Res (Phila) 3 2010 1435 1442
220. Y. Xi, G. Nakajima, E. Gavin, and et al. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples RNA 13 2007 1668 1674
221. H. Shibuya, H. Iinuma, R. Shimada, and et al. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer Oncology 79 2010 313 320
222. S. Kjaer-Frifeldt, T.F. Hansen, B.S. Nielsen, and et al. Danish Colorectal Cancer Group. The prognostic importance of miR-21 in stage II colon cancer: a population-based study Br J Cancer 107 2012 1169 1174
223. V. Kulda, M. Pesta, O. Topolcan, and et al. Relevance of miR-21 and miR-143 expression in tissue samples of colorectal carcinoma and its liver metastases Cancer Genet Cytogenet 200 2010 154 160
224. L.C. Bovell, C. Shanmugam, B.D. Putcha, and et al. The prognostic value of microRNAs varies with patient race/ethnicity and stage of colorectal cancer Clin Cancer Res 19 2013 3955 3965
225. J.X. Zhang, W. Song, Z.H. Chen, and et al. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis Lancet Oncol 14 2013 1295 1306
226. N. Nishida, S. Yamashita, K. Mimori, and et al. MicroRNA-10b is a prognostic indicator in colorectal cancer and confers resistance to the chemotherapeutic agent 5-fluorouracil in colorectal cancer cells Ann Surg Oncol 19 2012 3065 3071
227. K. Hur, Y. Toiyama, A.J. Schetter, and et al. Identification of a metastasis-specific microRNA signature in human colorectal cancer J Natl Cancer Inst 107 2015
228. M. Valladares-Ayerbes, M. Blanco, M. Haz, and et al. Prognostic impact of disseminated tumor cells and microRNA-17-92 cluster deregulation in gastrointestinal cancer Int J Oncol 39 2011 1253 1264
229. G. Yu, J.Q. Tang, M.L. Tian, and et al. Prognostic values of the miR-17-92 cluster and its paralogs in colon cancer J Surg Oncol 106 2012 232 237
230. L. Fang, H. Li, L. Wang, and et al. MicroRNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression Oncotarget 5 2014 2974 2987
231. A. Weissmann-Brenner, M. Kushnir, G. Lithwick Yanai, and et al. Tumor microRNA-29a expression and the risk of recurrence in stage II colon cancer Int J Oncol 40 2012 2097 2103
232. W. Tang, Y. Zhu, J. Gao, and et al. MicroRNA-29a promotes colorectal cancer metastasis by regulating matrix metalloproteinase 2 and E-cadherin via KLF4 Br J Cancer 110 2014 450 458
233. M.H. Yang, J. Yu, N. Chen, and et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2 PLoS One 8 2013 e85353
234. H. Igarashi, H. Kurihara, K. Mitsuhashi, and et al. Association of microRNA-31-5p with clinical efficacy of anti-EGFR therapy in patients with metastatic colorectal cancer Ann Surg Oncol 22 2015 2640 2648
235. H. Liu, L. Du, Z. Wen, Y. Yang, and et al. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value Int J Colorectal Dis 28 2013 697 703
236. S. Wang, M.H. Yang, X.Y. Wang, and et al. Increased expression of miRNA-182 in colorectal carcinoma: an independent and tissue-specific prognostic factor Int J Clin Exp Pathol 7 2014 3498 3503
237. H. Guo, Y. Chen, X. Hu, and et al. The regulation of Toll-like receptor 2 by miR-143 suppresses the invasion and migration of a subset of human colorectal carcinoma cells Mol Cancer 12 2013 77
238. M.J. Wang, Y. Li, R. Wang, and et al. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer Int J Colorectal Dis 28 2013 183 189
239. T. Jinushi, Y. Shibayama, I. Kinoshita, and et al. Low expression levels of microRNA-124-5p correlated with poor prognosis in colorectal cancer via targeting of SMC4 Cancer Med 3 2014 1544 1552
240. A. Figueredo, M.E. Coombes, S. Mukherjee, and et al. Adjuvant therapy for completely resected stage II colon cancer Cochrane Database Syst Rev 2008 CD005390
241. A.B. Benson III, D. Schrag, M.R. Somerfield, and et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer J Clin Oncol 22 2004 3408 3419
242. T. Schepeler, J.T. Reinert, M.S. Ostenfeld, and et al. Diagnostic and prognostic microRNAs in stage II colon cancer Cancer Res 68 2008 6416 6424
243. N. Oue, K. Anami, A.J. Schetter, and et al. High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer Int J Cancer 134 2014 1926 1934
244. T.F. Hansen, S. Kjaer-Frifeldt, R.D. Christensen, and et al. Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort Br J Cancer 111 2014 1285 1292
245. B.S. Nielsen, S. Jorgensen, J.U. Fog, and et al. High levels of microRNA-21 in the stroma of colorectal cancers predict short disease-free survival in stage II colon cancer patients Clin Exp Metastasis 28 2011 27 38
246. A. Bardelli, and S. Siena Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer J Clin Oncol 28 2010 1254 1261
247. H. Hurwitz, L. Fehrenbacher, W. Novotny, and et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
248. L.B. Saltz, N.J. Meropol, P.J. Loehrer Sr., and et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor J Clin Oncol 22 2004 1201 1208
249. D. Cunningham, Y. Humblet, S. Siena, and et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer N Engl J Med 351 2004 337 345
250. G.J. Poston, J. Figueras, F. Giuliante, and et al. Urgent need for a new staging system in advanced colorectal cancer J Clin Oncol 26 2008 4828 4833
251. K. Kurokawa, T. Tanahashi, T. Iima, and et al. Role of miR-19b and its target mRNAs in 5-fluorouracil resistance in colon cancer cells J Gastroenterol 47 2012 883 895
252. H. Chai, M. Liu, R. Tian, and et al. miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines Acta Biochim Biophys Sin (Shanghai) 43 2011 217 225
253. N. Valeri, P. Gasparini, C. Braconi, and et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) Proc Natl Acad Sci U S A 107 2010 21098 21103
254. P. Faltejskova, A. Besse, S. Sevcikova, and et al. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells Int J Colorectal Dis 27 2012 1401 1408
255. J. Deng, W. Lei, J.C. Fu, and et al. Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro Biochem Biophys Res Commun 443 2014 789 795
256. J. Shang, F. Yang, Y. Wang, and et al. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells J Cell Biochem 115 2014 772 784
257. C.J. Wang, J. Stratmann, Z.G. Zhou, and et al. Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells BMC Cancer 10 2010 616
258. Y. Akao, S. Noguchi, A. Iio, and et al. Dysregulation of microRNA-34a expression causes drug-resistance to 5-FU in human colon cancer DLD-1 cells Cancer Lett 300 2011 197 204
259. H. Siemens, R. Jackstadt, M. Kaller, and et al. Repression of c-Kit by p53 is mediated by miR-34 and is associated with reduced chemoresistance, migration and stemness Oncotarget 4 2013 1399 1415
260. M. Karaayvaz, H. Zhai, and J. Ju miR-129 promotes apoptosis and enhances chemosensitivity to 5-fluorouracil in colorectal cancer Cell Death Dis 4 2013 e659
261. B. Song, Y. Wang, Y. Xi, K. Kudo, and et al. Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells Oncogene 28 2009 4065 4074
262. J. Zhang, H. Guo, H. Zhang, and et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene Friend leukemia virus integration 1 gene Cancer 117 2011 86 95
263. V. Boni, N. Bitarte, I. Cristobal, and et al. miR-192/miR-215 influence 5-fluorouracil resistance through cell cycle-mediated mechanisms complementary to its post-transcriptional thymidilate synthase regulation Mol Cancer Ther 9 2010 2265 2275
264. S. Toden, Y. Okugawa, T. Jascur, and et al. Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer Carcinogenesis 36 2015 355 367
265. S.T. Guo, C.C. Jiang, G.P. Wang, and et al. MicroRNA-497 targets insulin-like growth factor 1 receptor and has a tumour suppressive role in human colorectal cancer Oncogene 32 2013 1910 1920
266. N. Bitarte, E. Bandres, V. Boni, and et al. MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells Stem Cells 29 2011 1661 1671
267. X. Qian, J. Yu, Y. Yin, and et al. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers Cell Cycle 12 2013 1385 1394
268. L. Zhang, K. Pickard, V. Jenei, and et al. miR-153 supports colorectal cancer progression via pleiotropic effects that enhance invasion and chemotherapeutic resistance Cancer Res 73 2013 6435 6447
269. Y. Zhou, G. Wan, R. Spizzo, and et al. miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase Mol Oncol 8 2014 83 92
270. K. Xu, X. Liang, D. Cui, and et al. miR-1915 inhibits Bcl-2 to modulate multidrug resistance by increasing drug-sensitivity in human colorectal carcinoma cells Mol Carcinog 52 2013 70 78
271. G. Nakajima, K. Hayashi, Y. Xi, and et al. Non-coding microRNAs hsa-let-7g and hsa-miR-181b are associated with chemoresponse to S-1 in colon cancer Cancer Genomics Proteomics 3 2006 317 324
272. K. Liu, G. Li, C. Fan, and et al. Increased expression of microRNA-21and its association with chemotherapeutic response in human colorectal cancer J Int Med Res 39 2011 2288 2295
273. M. Takahashi, M. Cuatrecasas, F. Balaguer, and et al. The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer PLoS One 7 2012 e46684
274. G. Manceau, S. Imbeaud, R. Thiebaut, and et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy Clin Cancer Res 20 2014 3338 3347
275. T. Derrien, R. Johnson, G. Bussotti, and et al. The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression Genome Res 22 2012 1775 1789
276. C.P. Ponting, P.L. Oliver, and W. Reik Evolution and functions of long noncoding RNAs Cell 136 2009 629 641
277. L. Ma, V.B. Bajic, and Z. Zhang On the classification of long non-coding RNAs RNA Biol 10 2013 925 933
278. M. Guttman, and J.L. Rinn Modular regulatory principles of large non-coding RNAs Nature 482 2012 339 346
279. G. Yu, W. Yao, J. Wang, and et al. LncRNAs expression signatures of renal clear cell carcinoma revealed by microarray PLoS One 7 2012 e42377
280. E.A. Gibb, D.D. Becker-Santos, K.S. Enfield, and et al. Aberrant expression of long noncoding RNAs in cervical intraepithelial neoplasia Int J Gynecol Cancer 22 2012 1557 1563
281. A.L. Brunner, A.H. Beck, B. Edris, and et al. Transcriptional profiling of long non-coding RNAs and novel transcribed regions across a diverse panel of archived human cancers Genome Biol 13 2012 R75
282. R.A. Gupta, N. Shah, K.C. Wang, and et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis Nature 464 2010 1071 1076
283. K. Tanaka, G. Shiota, M. Meguro, and et al. Loss of imprinting of long QT intronic transcript 1 in colorectal cancer Oncology 60 2001 268 273
284. M.D. Xu, P. Qi, and X. Du Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application Mod Pathol 27 2014 1310 1320
285. R. Kogo, T. Shimamura, K. Mimori, and et al. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers Cancer Res 71 2011 6320 6326
286. M. Svoboda, J. Slyskova, M. Schneiderova, and et al. HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients Carcinogenesis 35 2014 1510 1515
287. P. Ji, S. Diederichs, W. Wang, and et al. MALAT-1, a novel noncoding RNA, and thymosin beta4 predict metastasis and survival in early-stage non-small cell lung cancer Oncogene 22 2003 8031 8041
288. H.T. Zheng, D.B. Shi, Y.W. Wang, and et al. High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer Int J Clin Exp Pathol 7 2014 3174 3181
289. T. Kogure, I.K. Yan, W.L. Lin, and et al. Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A mechanism of intercellular signaling in human hepatocellular cancer Genes Cancer 4 2013 261 272
290. K. Takahashi, I.K. Yan, H. Haga, and et al. Modulation of hypoxia-signaling pathways by extracellular linc-RoR J Cell Sci 127 2014 1585 1594
291. T. Arita, D. Ichikawa, H. Konishi, and et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer Anticancer Res 33 2013 3185 3193
292. S. Ren, F. Wang, J. Shen, and et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer Eur J Cancer 49 2013 2949 2959
293. Y.S. Tong, X.W. Wang, X.L. Zhou, and et al. Identification of the long non-coding RNA POU3F3 in plasma as a novel biomarker for diagnosis of esophageal squamous cell carcinoma Mol Cancer 14 2015 3
294. L. Dong, P. Qi, M.D. Xu, and et al. Circulating CUDR, LSINCT-5 and PTENP1 long non-coding rnas in sera distinguish patients with gastric cancer from healthy controls Int J Cancer 2015 [Epub ahead of press] http://dx.doi.org/10.1002/ijc.29484
295. M. Tanzer, B. Balluff, J. Distler, and et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions PLoS One 5 2010 e9061
296. W.M. Grady, A. Rajput, J.D. Lutterbaugh, and et al. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer Cancer Res 61 2001 900 902
297. R. Grutzmann, B. Molnar, C. Pilarsky, and et al. Sensitive detection of colorectal cancer in peripheral blood by septin 9 DNA methylation assay PLoS One 3 2008 e3759
298. T. deVos, R. Tetzner, F. Model, and et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer Clin Chem 55 2009 1337 1346
299. J.D. Warren, W. Xiong, A.M. Bunker, and et al. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer BMC Med 9 2011 133
300. D.A. Ahlquist, W.R. Taylor, D.W. Mahoney, and et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia Clin Gastroenterol Hepatol 10 2012 272 277
301. K. Toth, R. Wasserkort, F. Sipos, and et al. Detection of methylated septin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA PLoS One 9 2014 e115415
302. N.T. Potter, P. Hurban, M.N. White, and et al. Validation of a real-time PCR-based qualitative assay for the detection of methylated SEPT9 DNA in human plasma Clin Chem 60 2014 1183 1191
303. D.A. Johnson, R.L. Barclay, K. Mergener, and et al. Plasma Septin9 versus fecal immunochemical testing for colorectal cancer screening: a prospective multicenter study PLoS One 9 2014 e98238
304. A. Amiot, H. Mansour, I. Baumgaertner, and et al. The detection of the methylated Wif-1 gene is more accurate than a fecal occult blood test for colorectal cancer screening PLoS One 9 2014 e99233
305. M.R. Abbaszadegan, A. Tavasoli, A. Velayati, and et al. Stool-based DNA testing, a new noninvasive method for colorectal cancer screening, the first report from Iran World J Gastroenterol 13 2007 1528 1533
306. E. Chang, D.I. Park, Y.J. Kim, and et al. Detection of colorectal neoplasm using promoter methylation of ITGA4, SFRP2, and p16 in stool samples: a preliminary report in Korean patients Hepatogastroenterology 57 2010 720 727
307. C. Ausch, Y.H. Kim, K.D. Tsuchiya, and et al. Comparative analysis of PCR-based biomarker assay methods for colorectal polyp detection from fecal DNA Clin Chem 55 2009 1559 1563
308. Z.H. Huang, L.H. Li, F. Yang, and et al. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions World J Gastroenterol 13 2007 950 954
309. Y.H. Baek, E. Chang, Y.J. Kim, and et al. Stool methylation-specific polymerase chain reaction assay for the detection of colorectal neoplasia in Korean patients Dis Colon Rectum 52 2009 1452 1459 discussion 1459-1463
310. M. Oberwalder, M. Zitt, C. Wontner, and et al. SFRP2 methylation in fecal DNA-a marker for colorectal polyps Int J Colorectal Dis 23 2008 15 19
311. T. Nagasaka, N. Tanaka, H.M. Cullings, and et al. Analysis of fecal DNA methylation to detect gastrointestinal neoplasia J Natl Cancer Inst 101 2009 1244 1258
312. H. Zhang, Y.Q. Zhu, Y.Q. Wu, and et al. Detection of promoter hypermethylation of Wnt antagonist genes in fecal samples for diagnosis of early colorectal cancer World J Gastroenterol 20 2014 6329 6335
313. J. Zhang, S. Yang, Y. Xie, and et al. Detection of methylated tissue factor pathway inhibitor 2 and human long DNA in fecal samples of patients with colorectal cancer in China Cancer Epidemiol 36 2012 73 77
314. J.B. Kisiel, T.C. Yab, F.T. Nazer Hussain, and et al. Stool DNA testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease Aliment Pharmacol Ther 37 2013 546 554
315. D.A. Ahlquist, H. Zou, M. Domanico, and et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas Gastroenterology 142 2012 248 256 quiz e25-e26
316. M. Esteller, S. Gonzalez, R.A. Risques, and et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer J Clin Oncol 19 2001 299 304
317. K. Shima, K. Nosho, Y. Baba, and et al. Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review Int J Cancer 128 2011 1080 1094
318. K. Maeda, K. Kawakami, Y. Ishida, and et al. Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival Oncol Rep 10 2003 935 938
319. J.T. Liang, K.J. Chang, J.C. Chen, and et al. Hypermethylation of the p16 gene in sporadic T3N0M0 stage colorectal cancers: association with DNA replication error and shorter survival Oncology 57 1999 149 156
320. R.L. Ward, K. Cheong, S.L. Ku, and et al. Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability J Clin Oncol 21 2003 3729 3736
321. L. Barault, C. Charon-Barra, V. Jooste, and et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases Cancer Res 68 2008 8541 8546
322. M.P. Bihl, A. Foerster, A. Lugli, and et al. Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing J Transl Med 10 2012 173
323. M.R. Kohonen-Corish, J. Tseung, C. Chan, and et al. KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer Int J Cancer 134 2014 2820 2828
324. H. Mitomi, N. Fukui, N. Tanaka, and et al. Aberrant p16((INK4a)) methylation is a frequent event in colorectal cancers: prognostic value and relation to mRNA expression and immunoreactivity J Cancer Res Clin Oncol 136 2010 323 331
325. A.H. Cleven, S. Derks, M.X. Draht, and et al. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer Clin Cancer Res 20 2014 3261 3271
326. J.M. Yi, M. Dhir, L. Van Neste, and et al. Genomic and epigenomic integration identifies a prognostic signature in colon cancer Clin Cancer Res 17 2011 1535 1545
327. P. Moya, S. Esteban, A. Fernandez-Suarez, and et al. KiSS-1 methylation and protein expression patterns contribute to diagnostic and prognostic assessments in tissue specimens for colorectal cancer Tumour Biol 34 2013 471 479
328. G. Nakayama, K. Hibi, Y. Kodera, and et al. P16 methylation in serum as a potential marker for the malignancy of colorectal carcinoma Anticancer Res 27 2007 3367 3370
329. A. Herbst, M. Wallner, K. Rahmig, and et al. Methylation of helicase-like transcription factor in serum of patients with colorectal cancer is an independent predictor of disease recurrence Eur J Gastroenterol Hepatol 21 2009 565 569
330. A.B. Philipp, P. Stieber, D. Nagel, and et al. Prognostic role of methylated free circulating DNA in colorectal cancer Int J Cancer 131 2012 2308 2319
331. W.S. Samowitz, C. Sweeney, J. Herrick, and et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers Cancer Res 65 2005 6063 6069
332. J.H. Kim, S.H. Shin, H.J. Kwon, and et al. Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers Virchows Arch 455 2009 485 494
333. A.M. Dahlin, R. Palmqvist, M.L. Henriksson, and et al. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status Clin Cancer Res 16 2010 1845 1855
334. P. Jo, K. Jung, M. Grade, and et al. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer Surgery 151 2012 564 570
335. C.C. Simons, L.A. Hughes, K.M. Smits, and et al. A novel classification of colorectal tumors based on microsatellite instability, the CpG island methylator phenotype and chromosomal instability: implications for prognosis Ann Oncol 24 2013 2048 2056
336. J.M. Bae, J.H. Kim, N.Y. Cho, and et al. Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location Br J Cancer 109 2013 1004 1012
337. Y. Wang, Y. Long, Y. Xu, and et al. Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer Gastroenterol Res Pract 2014 2014 436985
338. K. Kawakami, A. Matsunoki, M. Kaneko, and et al. Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer Cancer Sci 102 2011 166 174
339. M. Scartozzi, I. Bearzi, A. Mandolesi, and et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients Br J Cancer 104 2011 1786 1790
340. A. Amatu, A. Sartore-Bianchi, and et al. Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer Clin Cancer Res 19 2013 2265 2272
341. E. Heitzer, M. Artl, M. Filipits, and et al. Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1 Mod Pathol 27 2014 906 915
342. S. Zanutto, S. Pizzamiglio, M. Ghilotti, and et al. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer Br J Cancer 110 2014 1001 1007
343. M. Du, S. Liu, D. Gu, and et al. Clinical potential role of circulating microRNAs in early diagnosis of colorectal cancer patients Carcinogenesis 35 2014 2723 2730
344. G. Basati, A. Emami Razavi, S. Abdi, and et al. Elevated level of microRNA-21 in the serum of patients with colorectal cancer Med Oncol 31 2014 205
345. T.O. Yau, C.W. Wu, Y. Dong, and et al. microRNA-221 and microRNA-18a identification in stool as potential biomarkers for the non-invasive diagnosis of colorectal carcinoma Br J Cancer 111 2014 1765 1771
346. C.W. Wu, S.C. Ng, Y. Dong, and et al. Identification of microRNA-135b in stool as a potential noninvasive biomarker for colorectal cancer and adenoma Clin Cancer Res 20 2014 2994 3002
347. X. Ge, Y. Chen, X. Liao, and et al. Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer Med Oncol 30 2013 588
348. Y. Takahashi, G. Sawada, J. Kurashige, and et al. Amplification of PVT-1 is involved in poor prognosis via apoptosis inhibition in colorectal cancers Br J Cancer 110 2014 164 171
349. Q. Deng, B. He, T. Gao, and et al. Up-regulation of 91H promotes tumor metastasis and predicts poor prognosis for patients with colorectal cancer PLoS One 9 2014 e103022
350. Y. Han, Y.N. Yang, H.H. Yuan, and et al. UCA1, a long non-coding RNA up-regulated in colorectal cancer influences cell proliferation, apoptosis and cell cycle istribution Pathology 46 2014 396 401
351. M.D. Xu, P. Qi, W.W. Weng, and et al. Long non-coding RNA LSINCT5 predicts negative prognosis and exhibits oncogenic activity in gastric cancer Medicine (Baltimore) 93 2014 e303
352. G.A. Calin, C.G. Liu, M. Ferracin, and et al. Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas Cancer Cell 12 2007 215 229
353. P. Qi, M.D. Xu, S.J. Ni, and et al. Low expression of LOC285194 is associated with poor prognosis in colorectal cancer J Transl Med 11 2013 122
354. P. Qi, M.D. Xu, S.J. Ni, and et al. Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients Mol Carcinog 54 2015 742 750
355. D. Shi, H. Zheng, C. Zhuo, and et al. Low expression of novel lncRNA RP11-462C24.1 suggests a biomarker of poor prognosis in colorectal cancer Med Oncol 31 2014 31
356. D. Yin, X. He, E. Zhang, and et al. Long noncoding RNA GAS5 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer Med Oncol 31 2014 253
357. D.D. Yin, Z.J. Liu, E. Zhang, and et al. Decreased expression of long noncoding RNA MEG3 affects cell proliferation and predicts a poor prognosis in patients with colorectal cancer Tumour Biol 36 2015 4851 4859